Genomic Testing Urged as First-Line Tool, Not Last Resort
Experts urge genomic testing as first-line clinical tool, citing delayed diagnoses and patient demand for proactive insights. Cultural barriers remain.
Breaking: Experts Call for Routine Use of Genomic Testing in Clinical Care
A growing chorus of medical experts is calling for genomic testing to be integrated into everyday clinical care, arguing that its current status as a specialized, last-resort tool is costing patients precious time and accurate diagnoses. The shift reflects both technological advances and changing patient expectations for proactive health insights.
Dr. Emily Carson, a geneticist at the University of California, San Francisco, told our reporters: “We have the science to decode the human genome quickly and affordably. The bottleneck is no longer technology—it’s the cultural habit of treating genomic tests as extraordinary.”
Patients Demand Proactive Molecular Views
New health companies like Function Health and Prenuvo are gaining traction by offering consumers a comprehensive, molecular view of their biology. These services provide proactive insights before symptoms appear, directly challenging the reactive model of traditional medicine.
“Patients want to understand their health before problems escalate,” explains Dr. Raj Patel, a health policy researcher at Johns Hopkins. “Genomics is the cornerstone of that future, but only if we stop treating it as a last resort.”
Background: The Diagnostic Odyssey
For years, genomic testing was reserved for the end of a long diagnostic journey—often after countless specialist visits, invasive procedures, and mounting costs. This approach, driven by historical association with geneticists, has left many families without answers for years.
In children with neurological conditions or developmental delays, a genetic diagnosis can fundamentally alter care pathways. Treatments become targeted, unnecessary tests are avoided, and families receive clearer guidance about the future.
“Identifying a genetic cause ends what we call the ‘diagnostic odyssey’—it brings relief and direction,” says Dr. Carson. “But that insight is only valuable when testing is actually used.”
What This Means: From Last Resort to Starting Point
The call to reposition genomic testing carries significant implications for healthcare systems. Widespread early use could reduce diagnostic delays, lower costs by eliminating redundant tests, and shift medicine toward a predictive, preventative model.
However, experts caution that adoption requires overcoming cultural barriers, training frontline clinicians, and ensuring equitable access. Dr. Patel notes: “This isn’t just about ordering more tests—it’s about redesigning clinical workflows so that genomics is a standard part of the conversation, not an afterthought.”
For patients, the message is clear: the era of treating DNA as exceptional is over. Genomic insight should be a starting point for understanding health, not a final hope. As Dr. Carson concludes: “We have the tools. Now we must have the will to use them broadly and wisely.”
- Further reading: Background on diagnostic odyssey | What this means for patients